Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.
Add an action for QNTM.US, or sign in to see your action list.
| Name | Title | Year Born |
|---|---|---|
| Mr. Zeeshan Saeed | Co-Founder, CEO & Executive Non-Independent Co-Chairman | 1970 |
| Mr. Anthony John Durkacz | Co-Founder & Executive Non-Independent Co-Chairman | 1976 |
| Dr. Patrick Onyango Ph.D. | Director of Operations at U.S. | NA |
| Mr. Jason David Sawyer | Head of Finance & Mergers and Acquisitions | 1972 |
| Ms. Maryann Adesso | Corporate Secretary | NA |
| Randell Mack | President of FSD BioSciences | NA |
| Mr. Kevin Cassidy | Vice President of Quality-Lucid | NA |
Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.